nach oben

Erschienen in:

01.10.2016 | REVIEW

Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases

verfasst von: Shi-Yang Guan, Rui-Xue Leng, Muhammad Imran Khan, Humera Qureshi, Xiang-Pei Li, Dong-Qing Ye, Hai-Feng Pan

Erschienen in: Inflammation | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Autoimmune diseases contain a large number of pathologies characterized by various factors that contribute to a breakdown in self-tolerance. Cytokine-mediated immunity plays an essential role in the pathogenesis of varieties of autoimmune diseases. Recent studies reveal that interleukin-35 (IL-35), a newly identified cytokine of IL-12 family, is implicated in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), etc. In this review, we will discuss the biological features of IL-35 and summarize recent advances in the role of IL-35 in the development and pathogenesis of autoimmune diseases; the discoveries gained from these findings might translate into future therapies for these diseases.

Amari, A., M. Ebtekar, S.M. Moazzeni, M. Soleimani, L. Mohammadi Amirabad, M.T. Tahoori, and M. Massumi. 2015. In Vitro Generation of IL-35-expressing Human Wharton’s Jelly-derived Mesenchymal Stem Cells Using Lentiviral Vector. Iranian Journal of Allergy, Asthma, and Immunology 14(4): 416–426.PubMed

Aslam, R., Y. Hu, S. Gebremeskel, G.B. Segel, E.R. Speck, L. Guo, M. Kim, H. Ni, J. Freedman, and J.W. Semple. 2012. Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia. Blood 120(10): 2127–2132. doi:10.1182/blood-2012-02-413526.CrossRefPubMed

Baraut, J., L. Michel, F. Verrecchia, and D. Farge. 2010. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmunity Reviews 10(2): 65–73. doi:10.1016/j.autrev.2010.08.003.CrossRefPubMed

Bryan, C., Y. Howard, P. Brennan, C. Black, and A. Silman. 1996. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. British Journal of Rheumatology 35(11): 1122–1126.CrossRefPubMed

Cai, Z., C.K. Wong, J. Dong, M. Chu, D. Jiao, N.W. Kam, C.W. Lam, and L.S. Tam. 2015. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice. Clinical and Experimental Immunology 181(2): 253–266. doi:10.1111/cei.12639.CrossRefPubMedPubMedCentral

Collison, L.W., V. Chaturvedi, A.L. Henderson, P.R. Giacomin, C. Guy, J. Bankoti, D. Finkelstein, et al. 2010. IL-35-mediated induction of a potent regulatory T cell population. Nature Immunology 11(12): 1093–1101. doi:10.1038/ni.1952.CrossRefPubMedPubMedCentral

Collison, L.W., G.M. Delgoffe, C.S. Guy, K.M. Vignali, V. Chaturvedi, D. Fairweather, A.R. Satoskar, et al. 2012. The composition and signaling of the IL-35 receptor are unconventional. Nature Immunology 13(3): 290–299. doi:10.1038/ni.2227.CrossRefPubMedPubMedCentral

Collison, L.W., and D.A.A. Vignali. 2008. Interleukin-35: odd one out or part of the family? Immunological Reviews 226: 248–262.CrossRefPubMedPubMedCentral

Collison, L.W., C.J. Workman, T.T. Kuo, K. Boyd, Y. Wang, K.M. Vignali, R. Cross, D. Sehy, R.S. Blumberg, and D.A. Vignali. 2007. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450(7169): 566–569. doi:10.1038/nature06306.CrossRefPubMed

10.

Dantas, A.T., S.M. Goncalves, M.C. Pereira, R.S. Goncalves, C.D. Marques, M.J. Rego, R. Pitta Ida, A.L. Duarte, and M.G. Pitta. 2015. Increased IL-35 serum levels in systemic sclerosis and association with pulmonary interstitial involvement. Clinical Rheumatology 34(9): 1621–1625. doi:10.1007/s10067-015-3006-y.CrossRefPubMed

11.

Delgoffe, G.M., P.J. Murray, and D.A. Vignali. 2011. Interpreting mixed signals: the cell’s cytokine conundrum. Current Opinion in Immunology 23(5): 632–638. doi:10.1016/j.coi.2011.07.013.CrossRefPubMedPubMedCentral

12.

Dieker, J., L. Hilbrands, A. Thielen, H. Dijkman, J.H. Berden, and J. van der Vlag. 2015. Enhanced activation of dendritic cells by autologous apoptotic microvesicles in MRL/lpr mice. Arthritis Research and Therapy 17: 103. doi:10.1186/s13075-015-0617-2.CrossRefPubMedPubMedCentral

13.

Egwuagu, C.E., C.R. Yu, L. Sun, and R. Wang. 2015. Interleukin 35: Critical regulator of immunity and lymphocyte-mediated diseases. Cytokine and Growth Factor Reviews 26(5): 587–593. doi:10.1016/j.cytogfr.2015.07.013.CrossRefPubMedPubMedCentral

14.

Fonseca-Camarillo, G., J. Furuzawa-Carballeda, and J.K. Yamamoto-Furusho. 2015. Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with Inflammatory Bowel Disease. Cytokine 75(2): 389–402. doi:10.1016/j.cyto.2015.04.009.CrossRefPubMed

15.

Giovannetti, Antonello, Edoardo Rosato, Cristina Renzi, Angela Maselli, Lucrezia Gambardella, Anna Maria Giammarioli, Paolo Palange, et al. 2010. Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Clinical Immunology 137(1): 122–133. doi:10.1016/j.clim.2010.06.004.CrossRefPubMed

16.

Hunter, C.A. 2005. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nature Reviews Immunology 5(7): 521–531. doi:10.1038/nri1648.CrossRefPubMed

17.

Jiang, N., M. Li, and X. Zeng. 2014. Correlation of Th17 cells and CD4(+)CD25(+) regulatory T cells with clinical parameters in patients with systemic sclerosis. Chinese Medical Journal 127(20): 3557–3561.PubMed

18.

Jones, L.L., and D.A.A. Vignali. 2011. Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. Immunologic Research 51(1): 5–14. doi:10.1007/s12026-011-8209-y.CrossRefPubMedPubMedCentral

19.

Kalampokis, I., A. Yoshizaki, and T. F. Tedder. 2013. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther 15 Suppl 1:S1. doi:10.1186/ar3907 ar3907

20.

Kochetkova, I., S. Golden, K. Holderness, G. Callis, and D.W. Pascual. 2010. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. Journal of Immunology 184(12): 7144–7153. doi:10.4049/jimmunol.0902739.CrossRef

21.

Kochetkova, I., T. Thornburg, G. Callis, K. Holderness, M. Maddaloni, and D.W. Pascual. 2014. Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27. Journal of Immunology 192(2): 804–816. doi:10.4049/jimmunol.1302018.CrossRef

22.

Koutsokeras, T., and T. Healy. 2014. Systemic lupus erythematosus and lupus nephritis. Nature Reviews Drug Discovery 13(3): 173–174. doi:10.1038/nrd4227.CrossRefPubMed

23.

Langrish, C.L., B.S. McKenzie, N.J. Wilson, R. de Waal Malefyt, R.A. Kastelein, and D.J. Cua. 2004. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunology Reviews 202: 96–105. doi:10.1111/j.0105-2896.2004.00214.x.CrossRef

24.

Lee, S.Y., S.H. Lee, E.J. Yang, E.K. Kim, J.K. Kim, D.Y. Shin, and M.L. Cho. 2015. Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance. PloS One 10(9), e0135858. doi:10.1371/journal.pone.0135858.CrossRefPubMedPubMedCentral

25.

Leng, R.X., H.F. Pan, G.M. Chen, C. Wang, W.Z. Qin, L.L. Chen, J.H. Tao, and D.Q. Ye. 2010. IL-23: a promising therapeutic target for systemic lupus erythematosus. Archives of Medical Research 41(3): 221–225. doi:10.1016/j.arcmed.2010.02.011.CrossRefPubMed

26.

LeRoy, E.C., C. Black, R. Fleischmajer, S. Jablonska, T. Krieg, T.A. Medsger Jr., N. Rowell, and F. Wollheim. 1988. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. Journal of Rheumatology 15(2): 202–205.PubMed

27.

Li, Y., X. Pan, X. Peng, S. Li, Y. Zhou, X. Zheng, and M. Li. 2015. Adenovirus-mediated interleukin-35 gene transfer suppresses allergic airway inflammation in a murine model of asthma. Inflammation Research 64(10): 767–774. doi:10.1007/s00011-015-0858-1.CrossRefPubMed

28.

Li, Y., Y. Wang, Y. Liu, X. Zuo, and X. Lu. 2014. The possible role of the novel cytokines il-35 and il-37 in inflammatory bowel disease. Mediators of Inflammation 2014: 136329. doi:10.1155/2014/136329.PubMedPubMedCentral

29.

Li, Y., S. Wu, S. Jiang, T. Lin, L. Xia, H. Shen, and J. Lu. 2016. Interleukin-35 (IL-35) inhibits proliferation and promotes apoptosis of fibroblast-like synoviocytes isolated from mice with collagen-induced arthritis. Molecular Biology Reports 43(9): 947–956. doi:10.1007/s11033-016-4034-7.CrossRefPubMed

30.

Lim, J.Y., K.I. Im, E.S. Lee, N. Kim, Y.S. Nam, Y.W. Jeon, and S.G. Cho. 2016. Enhanced immunoregulation of mesenchymal stem cells by IL-10-producing type 1 regulatory T cells in collagen-induced arthritis. Science Reports 6: 26851. doi:10.1038/srep26851.CrossRef

31.

Liu, B., H. Zhao, M.C. Poon, Z. Han, D. Gu, M. Xu, H. Jia, R. Yang, and Z.C. Han. 2007. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. European Journal of Haematology 78(2): 139–143. doi:10.1111/j.1600-0609.2006.00780.x.PubMed

32.

Ma, X., and G. Trinchieri. 2001. Regulation of interleukin-12 production in antigen-presenting cells. Advances in Immunology 79: 55–92.CrossRefPubMed

33.

Mauri, C., and K. Nistala. 2014. Interleukin-35 takes the ‘B’ line. Nature Medicine 20(6): 580–581. doi:10.1038/nm.3594.CrossRefPubMed

34.

McInnes, I.B., and G. Schett. 2011. The pathogenesis of rheumatoid arthritis. New England Journal of Medicine 365(23): 2205–2219. doi:10.1056/NEJMra1004965.CrossRefPubMed

35.

McNamee, E.N., J.C. Masterson, M. Veny, C.B. Collins, P. Jedlicka, F.R. Byrne, G.Y. Ng, and J. Rivera-Nieves. 2015. Chemokine receptor CCR7 regulates the intestinal TH1/TH17/Treg balance during Crohn’s-like murine ileitis. Journal of Leukocyte Biology 97(6): 1011–1022. doi:10.1189/jlb.3HI0614-303R.CrossRefPubMedPubMedCentral

36.

Mirshafiey, A., and M. Mohsenzadegan. 2009. TGF-beta as a promising option in the treatment of multiple sclerosis. Neuropharmacology 56(6–7): 929–936.CrossRefPubMed

37.

Mok, C.C., and C.S. Lau. 2003. Pathogenesis of systemic lupus erythematosus. Journal of Clinical Pathology 56(7): 481–490.CrossRefPubMedPubMedCentral

38.

Nakano, S., S. Morimoto, S. Suzuki, H. Tsushima, K. Yamanaka, I. Sekigawa, and Y. Takasaki. 2015. Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. Rheumatology (Oxford) 54(8): 1498–1506. doi:10.1093/rheumatology/keu528.CrossRef

39.

Niedbala, W., X.Q. Wei, B. Cai, A.J. Hueber, B.P. Leung, I.B. McInnes, and F.Y. Liew. 2007. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. European Journal of Immunology 37(11): 3021–3029. doi:10.1002/eji.200737810.CrossRefPubMed

40.

Ning-Wei, Z. 2010. Interleukin (IL)-35 is raising our expectations. Revista Medica De Chile 138(6): 758–766.PubMed

41.

Niu, Q., B. Cai, Z.C. Huang, Y.Y. Shi, and L.L. Wang. 2012. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatology International 32(9): 2731–2736. doi:10.1007/s00296-011-1984-x.CrossRefPubMed

42.

O’Shea, J.J., and W.E. Paul. 2002. Regulation of T(H)1 differentiation—controlling the controllers. Nature Immunology 3(6): 506–508. doi:10.1038/ni0602-506.CrossRefPubMed

43.

Olsson, B., P.O. Andersson, M. Jernas, S. Jacobsson, B. Carlsson, L.M. Carlsson, and H. Wadenvik. 2003. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nature Medicine 9(9): 1123–1124. doi:10.1038/nm921.CrossRefPubMed

44.

Pan, H.F., J.H. Tao, and D.Q. Ye. 2010. Therapeutic potential of IL-27 in systemic lupus erythematosus. Expert Opinion on Therapeutic Targets 14(5): 479–484. doi:10.1517/14728221003769911.CrossRefPubMed

45.

Pan, Hai-Feng, Xiang-Pei Li, Song Guo Zheng, and Dong-Qing Ye. 2013. Emerging role of interleukin-22 in autoimmune diseases. Cytokine & Growth Factor Reviews 24(1): 51–57. doi:10.1016/j.cytogfr.2012.07.002.CrossRef

46.

Pittenger, M.F., A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, J.D. Mosca, M.A. Moorman, D.W. Simonetti, S. Craig, and D.R. Marshak. 1999. Multilineage potential of adult human mesenchymal stem cells. Science 284(5411): 143–147.CrossRefPubMed

47.

Podolsky, D.K. 2002. Inflammatory bowel disease. New England Journal of Medicine 347(6): 417–429. doi:10.1056/NEJMra020831.CrossRefPubMed

48.

Rasmusson, I., O. Ringden, B. Sundberg, and K. Le Blanc. 2003. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76(8): 1208–1213. doi:10.1097/01.TP.0000082540.43730.80.CrossRefPubMed

49.

Renner, K., F.J. Hermann, K. Schmidbauer, Y. Talke, M. Rodriguez Gomez, G. Schiechl, J. Schlossmann, H. Bruhl, H.J. Anders, and M. Mack. 2015. IL-3 contributes to development of lupus nephritis in MRL/lpr mice. Kidney International 88(5): 1088–1098. doi:10.1038/ki.2015.196.CrossRefPubMed

50.

Rubio-Rivas, M., C. Royo, C.P. Simeon, X. Corbella, and V. Fonollosa. 2014. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Seminars in Arthritis and Rheumatism 44(2): 208–219. doi:10.1016/j.semarthrit.2014.05.010.CrossRefPubMed

51.

Sakakura, M., H. Wada, I. Tawara, T. Nobori, T. Sugiyama, N. Sagawa, and H. Shiku. 2007. Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thrombosis Research 120(2): 187–193. doi:10.1016/j.thromres.2006.09.008.CrossRefPubMed

52.

Semple, J.W. 2002. Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Reviews 16(1): 9–12. doi:10.1054/blre.2001.0172.CrossRefPubMed

53.

Shen, P., T. Roch, V. Lampropoulou, R.A. O’Connor, U. Stervbo, E. Hilgenberg, S. Ries, et al. 2014. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507(7492): 366–370. doi:10.1038/nature12979.CrossRefPubMedPubMedCentral

54.

Shimomatsu, T., N. Kanazawa, N. Mikita, Y. Nakatani, H. J. Li, Y. Inaba, T. Ikeda, T. Kondo, and F. Furukawa. 2016. The effect of hydroxychloroquine on lupus erythematosus-like skin lesions in MRL/lpr mice. Modern Rheumatology:1–5. doi:10.3109/14397595.2016.1140711

55.

Talaat, R.M., S.F. Mohamed, I.H. Bassyouni, and A.A. Raouf. 2015. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. Cytokine 72(2): 146–153. doi:10.1016/j.cyto.2014.12.027.CrossRefPubMed

56.

Toriani-Terenzi, C., and E. Fagiolo. 2005. IL-10 and the cytokine network in the pathogenesis of human autoimmune hemolytic anemia. Annals of the New York Academy of Sciences 1051: 29–44. doi:10.1196/annals.1361.044.CrossRefPubMed

57.

Wang, R.X., C.R. Yu, I.M. Dambuza, R.M. Mahdi, M.B. Dolinska, Y.V. Sergeev, P.T. Wingfield, S.H. Kim, and C.E. Egwuagu. 2014. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nature Medicine 20(6): 633–641. doi:10.1038/nm.3554.CrossRefPubMedPubMedCentral

58.

Wang, W., S. Shao, Z. Jiao, M. Guo, H. Xu, and S. Wang. 2012. The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatology International 32(4): 887–893. doi:10.1007/s00296-010-1710-0.CrossRefPubMed

59.

Whitehead, G.S., R.H. Wilson, K. Nakano, L.H. Burch, H. Nakano, and D.N. Cook. 2012. IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. The Journal of Allergy and Clinical Immunology 129(1): 207–215. doi:10.1016/j.jaci.2011.08.009. e201-205.CrossRefPubMed

60.

Wirtz, S., U. Billmeier, T. McHedlidze, R.S. Blumberg, and M.F. Neurath. 2011. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology 141(5): 1875–1886. doi:10.1053/j.gastro.2011.07.040.CrossRefPubMedPubMedCentral

61.

Xavier, R.J., D.K. Podolsk, and D.K. Podolsky. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448(7152): 427–434. doi:10.1038/nature06005.CrossRefPubMed

62.

Yang, Y., M. Xuan, X. Zhang, D. Zhang, R. Fu, F. Zhou, L. Ma, et al. 2014. Decreased IL-35 levels in patients with immune thrombocytopenia. Human Immunology 75(8): 909–913. doi:10.1016/j.humimm.2014.06.019.CrossRefPubMed

63.

Yoshida, H., and Y. Miyazaki. 2008. Regulation of immune responses by interleukin-27. Immunology Reviews 226: 234–247. doi:10.1111/j.1600-065X.2008.00710.x.CrossRef

64.

Yoshimura, T., A. Takeda, S. Hamano, Y. Miyazaki, I. Kinjyo, T. Ishibashi, A. Yoshimura, and H. Yoshida. 2006. Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. Journal of Immunology 177(8): 5377–5385.CrossRef

65.

Yu, J., S. Heck, V. Patel, J. Levan, Y. Yu, J.B. Bussel, and K. Yazdanbakhsh. 2008. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 112(4): 1325–1328. doi:10.1182/blood-2008-01-135335.CrossRefPubMedPubMedCentral

66.

Yu, S., C. Liu, L. Li, T. Tian, M. Wang, Y. Hu, C. Yuan, L. Zhang, C. Ji, and D. Ma. 2015. Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia. Laboratory Investigation 95(2): 157–167. doi:10.1038/labinvest.2014.142.CrossRefPubMed

67.

Zhou, L., F. Xu, C. Chang, Y. Tao, L. Song, and X. Li. 2016. Interleukin-17-producing CD4+ T lymphocytes are increased in patients with primary immune thrombocytopenia. Blood Coagulation and Fibrinolysis 27(3): 301–307. doi:10.1097/MBC.0000000000000423.CrossRefPubMed

68.

Zhou, X., N. Kong, H. Zou, D. Brand, X. Li, Z. Liu, and S.G. Zheng. 2011. Therapeutic potential of TGF-beta-induced CD4(+) Foxp3(+) regulatory T cells in autoimmune diseases. Autoimmunity 44(1): 43–50. doi:10.3109/08916931003782163.CrossRefPubMed

69.

Zhu, M., H. Mo, D. Li, X. Luo, and L. Zhang. 2013. Th17/Treg imbalance induced by increased incidence of atherosclerosis in patients with systemic lupus erythematosus (SLE). Clinical Rheumatology 32(7): 1045–1052. doi:10.1007/s10067-013-2237-z.CrossRefPubMed

Titel: Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases
verfasst von: Shi-Yang Guan
Rui-Xue Leng
Muhammad Imran Khan
Humera Qureshi
Xiang-Pei Li
Dong-Qing Ye
Hai-Feng Pan
Publikationsdatum: 01.10.2016
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 1/2017
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-016-0453-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Heme-Exposed Pooled Therapeutic IgG Improves Endotoxemia Survival

Angiotensin II-Induced Early and Late Inflammatory Responses Through NOXs and MAPK Pathways

The Role of IL-33 on LPS-Induced Acute Lung Injury in Mice

Soluble Epoxide Hydrolase Inhibitor Suppresses the Expression of Triggering Receptor Expressed on Myeloid Cells-1 by Inhibiting NF-kB Activation in Murine Macrophage

Brain-Derived Neurotrophic Factor Inhibits Peptidoglycan-Induced Inflammatory Cytokine Expression in Human Dental Pulp Cells